HRP980263B1 - Novel form of s-omeprazole - Google Patents

Novel form of s-omeprazole

Info

Publication number
HRP980263B1
HRP980263B1 HR980263A HRP980263A HRP980263B1 HR P980263 B1 HRP980263 B1 HR P980263B1 HR 980263 A HR980263 A HR 980263A HR P980263 A HRP980263 A HR P980263A HR P980263 B1 HRP980263 B1 HR P980263B1
Authority
HR
Croatia
Prior art keywords
omeprazole
novel form
novel
Prior art date
Application number
HR980263A
Other languages
English (en)
Inventor
Hanna Cotton
Anders Kronstroem
Anders Mattson
Eva Moeller
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP980263(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP980263A2 publication Critical patent/HRP980263A2/hr
Publication of HRP980263B1 publication Critical patent/HRP980263B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
HR980263A 1997-05-30 1998-05-15 Novel form of s-omeprazole HRP980263B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702065A SE510650C2 (sv) 1997-05-30 1997-05-30 Ny förening

Publications (2)

Publication Number Publication Date
HRP980263A2 HRP980263A2 (en) 1999-02-28
HRP980263B1 true HRP980263B1 (en) 2002-02-28

Family

ID=20407186

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980263A HRP980263B1 (en) 1997-05-30 1998-05-15 Novel form of s-omeprazole

Country Status (43)

Country Link
US (6) US6369085B1 (cs)
EP (2) EP1273581B1 (cs)
JP (2) JP4002303B2 (cs)
KR (2) KR100527804B1 (cs)
CN (1) CN1161351C (cs)
AR (2) AR012717A1 (cs)
AT (2) ATE239011T1 (cs)
AU (1) AU722839B2 (cs)
BR (1) BR9809509A (cs)
CA (2) CA2521391C (cs)
CY (1) CY2012029I1 (cs)
CZ (1) CZ297585B6 (cs)
DE (3) DE69814069T3 (cs)
DK (2) DK1273581T3 (cs)
DZ (1) DZ2495A1 (cs)
EE (1) EE03875B1 (cs)
EG (1) EG24291A (cs)
ES (2) ES2195345T7 (cs)
HR (1) HRP980263B1 (cs)
HU (1) HU225987B1 (cs)
ID (1) ID29306A (cs)
IL (1) IL132947A0 (cs)
IS (2) IS2142B (cs)
LU (2) LU91871I2 (cs)
MA (1) MA26500A1 (cs)
ME (3) MEP18008A (cs)
MY (2) MY127793A (cs)
NO (3) NO317518B1 (cs)
NZ (1) NZ500991A (cs)
PL (1) PL193546B1 (cs)
PT (2) PT1273581E (cs)
RS (2) RS50005B (cs)
RU (1) RU2184115C2 (cs)
SA (2) SA05260296B1 (cs)
SE (1) SE510650C2 (cs)
SI (2) SI0984957T1 (cs)
SK (2) SK285137B6 (cs)
TN (1) TNSN98074A1 (cs)
TR (1) TR199902934T2 (cs)
TW (1) TW538040B (cs)
UA (1) UA60334C2 (cs)
WO (1) WO1998054171A1 (cs)
ZA (1) ZA984179B (cs)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US7345061B2 (en) 2002-03-05 2008-03-18 Astrazeneca Ab Alkylammonium salts of omeprazole and esomeprazole
WO2003089408A2 (en) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
EP1515963B1 (en) 2002-06-27 2007-02-14 Dr. Reddy's Laboratories Ltd. A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
CN100378093C (zh) * 2002-06-27 2008-04-02 雷迪实验室有限公司 一种制备包括无定形艾美拉唑及其盐在内的光学纯或光学浓缩的亚砜化合物的方法
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
WO2004020436A1 (en) * 2002-08-30 2004-03-11 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
EP2596792A1 (en) * 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
BR0315574A (pt) * 2002-10-22 2005-09-20 Ranbaxy Lab Ltd Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
EP1583507A2 (en) * 2003-01-07 2005-10-12 Ranbaxy Laboratories Limited Magnesium salt of imidazole derivative
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
EP1633736A1 (en) 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
AU2004260832A1 (en) * 2003-07-23 2005-02-10 Nycomed Gmbh Alkaline salts of proton pump inhibitors
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP1715854A2 (en) * 2004-02-18 2006-11-02 Allergan, Inc. Prodrugs for the intravenous administration of proton pump inhibitors
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US8658799B2 (en) * 2004-06-24 2014-02-25 Astrazeneca Ab Process for the preparation of crystalline modifications for use in the preparation of esomeperazole sodium salt
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
EP1885711A1 (en) * 2005-05-06 2008-02-13 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
EP1891043A1 (en) * 2005-06-15 2008-02-27 Hetero Drugs Limited Amorphous esomeprazole hydrate
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
BRPI0617987A2 (pt) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
WO2007049914A1 (en) * 2005-10-26 2007-05-03 Hanmi Pharm. Co., Ltd. S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
US7576219B2 (en) * 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
WO2007148213A2 (en) * 2006-06-21 2007-12-27 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
GB2459393B (en) 2006-10-05 2010-09-08 Santarus Inc Novel capsule formulation for the proton pump inhibitor omeprazole
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
EP2114919A2 (en) 2007-01-31 2009-11-11 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation
EP2125783A2 (en) * 2007-02-21 2009-12-02 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
WO2008149204A1 (en) * 2007-06-07 2008-12-11 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
FR2920428B1 (fr) 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
US8106210B2 (en) * 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
CA2702356C (en) 2007-10-12 2014-02-11 Takeda Pharmaceuticals North America, Inc. Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2240496A4 (en) * 2008-02-01 2011-05-11 Reddys Lab Ltd Dr PREPARATION OF MAGNESIUM OF ESOMEPRAZOLE AND ITS HYDRATES
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) * 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
MX2011002515A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita.
CN101391993B (zh) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010150276A2 (en) * 2009-06-02 2010-12-29 Sun Pharmaceutical Industries Limited Process for preparing sulphoxide compounds
WO2010151216A1 (en) 2009-06-25 2010-12-29 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
JP2012531430A (ja) * 2009-06-25 2012-12-10 ポーゼン インコーポレイテッド アスピリン療法を必要とする患者を治療するための方法
WO2011012957A1 (en) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of esomeprazole magnesium dihydrate
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
CN102884178B (zh) 2009-12-08 2014-12-03 科德克希思公司 拉唑化合物的合成
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (fr) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
CN102241668B (zh) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 S-奥美拉唑盐
US9267159B2 (en) 2010-12-08 2016-02-23 Codexis, Inc. Biocatalysts and methods for the synthesis of armodafinil
CN102757421A (zh) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 埃索美拉唑的纯化方法
CN102911158B (zh) * 2011-07-31 2015-07-22 连云港润众制药有限公司 埃索美拉唑镁的晶型
CN102924435B (zh) * 2011-11-25 2014-06-25 成都自豪药业有限公司 S-奥美拉唑镁盐的晶型及其制备方法
WO2013088272A1 (en) * 2011-12-14 2013-06-20 Wockhardt Limited Pharmaceutical composition comprising esomeprazole magnesium dihydrate
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
CN104250243B (zh) * 2013-06-27 2016-12-28 四川国为制药有限公司 一种埃索美拉唑镁二水合物a晶型的制备方法
CN103570686B (zh) * 2013-10-14 2015-04-01 哈药集团技术中心 一种埃索美拉唑钠的合成及精制工艺
CN104725357A (zh) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 一种埃索美拉唑镁二水合物晶型b的制备方法
FR3018812A1 (fr) * 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
CN104447699A (zh) * 2014-12-10 2015-03-25 哈药集团技术中心 一种埃索美拉唑镁三水合物的制备方法
CN105111188B (zh) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 一种埃索美拉唑镁三水合物晶型的制备方法
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106397402B (zh) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 一种埃索美拉唑镁晶型化合物及其制备方法
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
WO2020040233A1 (ja) * 2018-08-21 2020-02-27 東和薬品株式会社 化合物の特定形状の結晶及びその製造方法
MX2021001905A (es) 2018-08-23 2021-04-28 Chong Kun Dang Pharmaceutical Corp Preparacion farmaceutica que tiene excelentes propiedades de disolucion, que contiene esomeprazol y bicarbonato de sodio.
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制
CN119320380B (zh) * 2024-10-14 2025-11-25 山东益康药业股份有限公司 奥美拉唑与2,6-二羟基苯甲酸的共晶物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US5244891A (en) * 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
FR2719045B1 (fr) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Procédé de préparation d'acide L-aspartique à partir d'aspartate d'ammonium.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
EP0723436B1 (en) 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
PT792879E (pt) * 1994-11-14 2001-08-30 Daiichi Seiyaku Co Processo para a preparacao de dicloridrato-3,5-hidrato do 3-¬2-¬4-(3-cloro-2-metilfenil)-1-piperazinil|-etil|-5,6-dimetoxi-1-(4-imidazolilmetil)-1h-indazol
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (zh) 1995-05-25 1999-03-10 常州市第四制药厂 奥美拉唑盐水合物及其制备方法
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Also Published As

Publication number Publication date
RS50067B (sr) 2009-01-22
DE69829511T2 (de) 2006-02-16
JP2007161734A (ja) 2007-06-28
HUP0001849A2 (hu) 2002-05-29
PT984957E (pt) 2003-07-31
DK0984957T3 (da) 2003-06-30
DE69814069T3 (de) 2014-03-27
KR20010013126A (ko) 2001-02-26
CA2521391A1 (en) 1998-12-03
IS2142B (is) 2006-09-15
CY2012029I2 (el) 2015-08-05
CA2290963C (en) 2006-03-28
HK1051681A1 (en) 2003-08-15
KR20050042827A (ko) 2005-05-10
EP0984957B1 (en) 2003-05-02
US8466175B2 (en) 2013-06-18
US6369085B1 (en) 2002-04-09
ID29306A (id) 2001-08-16
PL193546B1 (pl) 2007-02-28
DE69829511D1 (de) 2005-04-28
AU7793598A (en) 1998-12-30
US7745466B2 (en) 2010-06-29
ES2195345T3 (es) 2003-12-01
TNSN98074A1 (fr) 2005-03-15
US20050075369A1 (en) 2005-04-07
US20120252847A1 (en) 2012-10-04
IL132947A0 (en) 2001-03-19
UA60334C2 (uk) 2003-10-15
PL337180A1 (en) 2000-08-14
SK162599A3 (en) 2000-06-12
AR012717A1 (es) 2000-11-08
DE69814069T2 (de) 2004-04-01
MY127793A (en) 2006-12-29
HRP980263A2 (en) 1999-02-28
SE9702065D0 (sv) 1997-05-30
ATE291574T1 (de) 2005-04-15
LU92017I2 (fr) 2012-08-06
US20020198239A1 (en) 2002-12-26
RU2184115C2 (ru) 2002-06-27
IS2774B (is) 2012-03-15
EP0984957A1 (en) 2000-03-15
NO995852D0 (no) 1999-11-29
EP1273581A1 (en) 2003-01-08
EG24291A (en) 2009-01-08
DZ2495A1 (fr) 2003-01-25
NO2011010I1 (no) 2011-06-20
JP2002501529A (ja) 2002-01-15
JP4002303B2 (ja) 2007-10-31
US20080255363A1 (en) 2008-10-16
NO995852L (no) 2000-01-31
MY120745A (en) 2005-11-30
SA05260296B1 (ar) 2008-04-16
CY2012029I1 (el) 2015-08-05
TW538040B (en) 2003-06-21
ZA984179B (en) 1998-11-30
BR9809509A (pt) 2000-06-20
DE69814069D1 (de) 2003-06-05
NO317518B1 (no) 2004-11-08
CN1161351C (zh) 2004-08-11
EP1273581B1 (en) 2005-03-23
IS8368A (is) 2006-03-22
TR199902934T2 (xx) 2000-04-21
NO2012011I1 (no) 2012-06-18
CN1258295A (zh) 2000-06-28
ME00198B (me) 2011-02-10
EE03875B1 (et) 2002-10-15
US8076361B2 (en) 2011-12-13
ATE239011T1 (de) 2003-05-15
SE510650C2 (sv) 1999-06-14
HUP0001849A3 (en) 2003-02-28
CA2290963A1 (en) 1998-12-03
RS20070459A (sr) 2008-06-05
HU0001849D0 (cs) 2002-05-29
SK284837B6 (sk) 2005-12-01
KR100527804B1 (ko) 2005-11-15
NZ500991A (en) 2001-05-25
SA98190280B1 (ar) 2006-07-04
YU60999A (sh) 2002-03-18
EE9900550A (et) 2000-06-15
DE122012000017I1 (de) 2012-08-16
CA2521391C (en) 2009-09-29
WO1998054171A1 (en) 1998-12-03
AR059589A2 (es) 2008-04-16
IS5272A (is) 1999-11-25
EP0984957B3 (en) 2013-09-18
US6677455B2 (en) 2004-01-13
HK1025962A1 (en) 2000-12-01
MEP18008A (en) 2010-10-10
MA26500A1 (fr) 2004-12-20
AU722839B2 (en) 2000-08-10
HU225987B1 (en) 2008-02-28
KR100540720B1 (ko) 2006-01-12
MEP24908A (en) 2010-10-10
PT1273581E (pt) 2005-06-30
SI1273581T1 (cs) 2005-08-31
SK285137B6 (sk) 2006-07-07
SE9702065L (sv) 1998-12-01
ES2195345T7 (es) 2014-01-15
ES2236407T3 (es) 2005-07-16
US20110130570A1 (en) 2011-06-02
WO1998054171A8 (en) 1999-12-23
SI0984957T1 (en) 2003-10-31
LU91871I2 (fr) 2011-11-21
CZ297585B6 (cs) 2007-01-10
DK1273581T3 (da) 2005-06-06
RS50005B (sr) 2008-09-29
US7411070B2 (en) 2008-08-12

Similar Documents

Publication Publication Date Title
EG24291A (en) Novel form of s-omeprazole
HUP0001547A3 (en) Novel form of s-omeprazole
PL339551A1 (en) Derivatives of rezorcin
EP1033994A4 (en) METHOD FOR PRODUCING BIOGINKGO
HUP0003737A3 (en) New process for the preparation of omeprazole
PL334769A1 (en) Derivatives of 5-aroylnaphtene
PL338777A1 (en) Derivative of piperidinylmethyloxazolydinone
ZA985064B (en) Derivatives of pentaerythrits
PL325816A1 (en) Novel derivatives of naphtylpiperazine
IL124387A0 (en) Preparation of 5-Methyleneoxazolines
HUP0101215A3 (en) Chrystalline form of paroxetine
GB2322372B (en) Preparation of 2-Mercaptothiazole
GB2329384B (en) Preparation of 1-chloro-1-cyclopropylethene
TW319017U (en) Improved structure of mousetraps
TW312301U (en) Improved structure of earmask
PL319263A1 (en) Novel derivative of pyrimidinylcarbazole
GB9702187D0 (en) Ware forming
PL327430A1 (en) Set of shaped components
GB9714286D0 (en) Brick
TW357554U (en) Improvement of shinguards
TW314733U (en) Structure of hairclip
TW316466U (en) Structure of hangtag
TW317745U (en) Improved structure of mini-duster
TW312131U (en) Improved structure of earflaps
TW323471U (en) Improved structure of hairclip

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: ASTRAZENECA AB, SE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20170418

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20180515